Resistance risk evaluation, "a European regulatory perspective"

被引:2
|
作者
Leonard, PK [1 ]
机构
[1] Cyanamid Int, B-5030 Gembloux, Belgium
关键词
D O I
10.1016/S0261-2194(00)00118-6
中图分类号
S3 [农学(农艺学)];
学科分类号
0901 ;
摘要
The European Union directive 91/414 on the inclusion of new and existing active substances requires an assessment of the potential risk of resistance being developed by target organisms and for management strategies to be introduced to address such risks. The European and Mediterranean Plant Protection Organisation (EPPO) worked with regulatory authorities and industry's Global Crop Protection Federation's (GCPF) Resistance Action Committees to develop a guideline that would satisfy these requirements. The new resistance risk analysis guideline was published in April 2000. Implementation of this guideline will force significant changes in the way crop protection products are developed. Applicants for registration of crop protection products will need to evaluate resistance risk and develop acceptable use patterns early in the development process. Registration applications for uses that are associated with an unacceptable resistance risk may be refused. In such cases, restriction or modification of supported use patterns to achieve acceptable levels of resistance risk, could result in use patterns which are no longer consistent with other elements of the registration dossier. It is therefore essential that resistance risk is evaluated early in development so that registration dossiers may be developed with this criteria in mind. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:905 / 909
页数:5
相关论文
共 50 条
  • [1] Risk ManagementA European Regulatory Perspective
    Jane N. S. Moseley
    Drug Safety, 2004, 27 : 499 - 508
  • [2] Risk management - A European regulatory perspective
    Moseley, JNS
    DRUG SAFETY, 2004, 27 (08) : 499 - 508
  • [3] Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective
    Arlett P.
    Postigo R.
    Janssen H.
    Spooner A.
    Pharmaceutical Medicine, 2014, 28 (6) : 309 - 315
  • [4] A Swedish regulatory perspective on European risk management
    Hedenmalm K.
    Alvan G.
    International Journal of Pharmaceutical Medicine, 2007, 21 (2) : 131 - 145
  • [5] Documenting High-Risk AI: A European Regulatory Perspective
    Hupont, Isabelle
    Micheli, Marina
    Delipetrev, Blagoj
    Gomez, Emilia
    Garrido, Josep Soler
    COMPUTER, 2023, 56 (05) : 18 - 27
  • [6] Rosiglitazone: a European regulatory perspective
    Blind, E.
    Dunder, K.
    de Graeff, P. A.
    Abadie, E.
    DIABETOLOGIA, 2011, 54 (02) : 213 - 218
  • [7] Rosiglitazone: a European regulatory perspective
    E. Blind
    K. Dunder
    P. A. de Graeff
    E. Abadie
    Diabetologia, 2011, 54 : 213 - 218
  • [8] Environmental Risk Assessment of Technical Mixtures Under the European Registration, Evaluation, Authorisation and Restriction of Chemicals-A Regulatory Perspective
    Galert, Wiebke
    Hassold, Enken
    INTEGRATED ENVIRONMENTAL ASSESSMENT AND MANAGEMENT, 2021, 17 (03) : 498 - 506
  • [9] REGULATORY REFORM AND LIBERALIZATION - A EUROPEAN PERSPECTIVE
    ENCAOUA, D
    INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 1991, 9 (01) : 1 - 7
  • [10] The European regulatory perspective on engineered nanomaterials
    Sokull-Kluettgen, Birgit
    TOXICOLOGY LETTERS, 2012, 211 : S13 - S13